Prices delayed by at least 15 minutes | Print
AC Immune SA (ACIU)
Common SharesThis share can be held in a Dealing accountISALifetime ISAJISASIPP
Company profile
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Address
EPFL Innovation Park
Building B
Lausanne
CHE
1015
Telephone
+4 121 3459121
Forecast key dates
| Name | Key Date |
|---|---|
| AC Immune SA First Quarter Earnings Results for 2025 | 2025-04-25T00:00:00 |
| AC Immune SA Annual General Meeting for 2025 | 2025-04-25T00:00:00 |
| AC Immune SA Annual Report for 2024 | 2025-03-14T00:00:00 |
| AC Immune SA Fourth Quarter Earnings Conference Call for 2024 | 2025-02-06T10:00:00 |
| AC Immune SA Fourth Quarter Earnings Result for 2024 | 2025-02-06T00:00:00 |
| AC Immune SA Third Quarter Earnings Results for 2024 | 2024-10-24T00:00:00 |
| AC Immune SA Second Quarter Earnings Results for 2024 | 2024-07-17T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| AC Immune SA First Quarter Earnings Results for 2024 | 2024-04-25T00:00:00 |
| AC Immune SA Annual General Meeting for 2024 | 2024-04-25T00:00:00 |
| AC Immune SA Annual Report for 2023 | 2024-03-14T00:00:00 |
| AC Immune SA Fourth Quarter Earnings Conference Call for 2023 | 2024-02-06T10:00:00 |
| AC Immune SA Fourth Quarter Earnings Result for 2023 | 2024-02-06T00:00:00 |
| AC Immune SA Third Quarter Earnings Results for 2023 | 2023-11-03T00:00:00 |
| AC Immune SA Second Quarter Earnings Results for 2023 | 2023-08-04T00:00:00 |
| AC Immune SA Annual General Meeting for 2023 | 2023-06-23T14:30:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.